| Literature DB >> 20350322 |
Leonard E Egede1, Joni L Strom, Valerie L Durkalski, Patrick D Mauldin, William P Moran.
Abstract
BACKGROUND: African Americans with Type 2 diabetes (T2DM) have higher prevalence of diabetes, poorer metabolic control, and greater risk for complications and death compared to American Whites. Poor outcomes in African Americans with T2DM can be attributed to patient, provider, and health systems level factors. Provider and health system factors account for <10% of variance in major diabetes outcomes including hemoglobin A1c (HbA1c), lipid control, and resource use. Key differences appear to be at the patient level. Of the patient level factors, consistent differences between African Americans and American Whites with T2DM have been found in diabetes knowledge, self-management skills, empowerment, and perceived control. A variety of interventions to improve diabetes self-management have been tested including: 1) knowledge interventions; 2) lifestyle interventions; 3) skills training interventions; and 4) patient activation and empowerment interventions. Most of these interventions have been tested individually, but rarely have they been tested in combination, especially among African Americans who have the greatest burden of diabetes related complications. This study provides a unique opportunity to address this gap in the literature. METHODS/Entities:
Mesh:
Substances:
Year: 2010 PMID: 20350322 PMCID: PMC2855561 DOI: 10.1186/1745-6215-11-35
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Data Collection Schedule
| Questionnaires/Measurements | Baseline Visit | 3-month Visit | 6-month visit | 12-month visit |
|---|---|---|---|---|
| HbA1c | X | X | X | X |
| Fasting lipid profile | X | X | X | X |
| Physical Activity | X | X | X | X |
| Diet | X | X | X | X |
| Medication Adherence (eCaps) | X | X | X | X |
| Self-Monitoring of Blood Glucose | X | X | X | |
| Blood Pressure | X | X | X | X |
| Resource Use/Cost | X | X | X | X |
| Body Composition (BOD POD) | X | X | ||
| Other Laboratory measurements | X | X | ||
| Anthropometric measurements | X | X | X | X |
| Diabetes Knowledge Questionnaire | X | X | X | X |
| Diabetes Empowerment Scale | X | X | X | X |
| Summary of Diabetes Self-Care Activities Scale | X | X | X | X |
| Treatment Credibility | X | X | ||
| Perceived Diabetes Self Efficacy Scale | X | X | X | X |
| Patient Demographics | X | |||
| Quality of life (SF-12) | X | X | ||
| Social support | X | X | ||
| Health Literacy | X | X | ||
| Depression (PHQ-9) | X | X | X | X |
| Medical Comorbidity (Charlson Index) | X | X | ||
| Morisky Medication Adherence Scale | X | X | X | X |
| Diabetes Fatalism Scale | X | X | X | X |
| Service Delivery Perceptions | X | X | ||
| Assessment of eCaps Use | X | X | X | |
Data Collection Measures
| Outcome | Test | Measurement |
|---|---|---|
| HbA1c/Fasting Lipid Profile | Blood specimens will be obtained at baseline, 3-, 6- and 12-months visits. | |
| Laboratory Measurements | Blood specimens will be obtained at baseline and 12-months visits. | |
| Physical Activity | The seven-day physical activity recall (PAR) will be used to measure of physical activity [ | |
| Diet | Dietary intake will be assessed using the Block 1998 Food Frequency Questionnaire [ | |
| Medication Adherence | The eCAP® electronic compliance monitor (Information Mediary Corporation, Ottawa, Canada) will serve as the primary measure of medication adherence for this study. | |
| Self-monitoring of Blood Glucose | Glucometer downloads will be used to assess self-monitoring adherence. | |
| Blood pressure measurements | Blood pressure readings will be obtained at baseline, 3-, 6- and 12-months by a trained RA using automated BP monitors (OMRON IntelliSense™ HEM-907XL) with the patient seated comfortably for 5 minutes prior to the measurements. | |
| Resource Utilization & Cost | The perspective of cost will be that of the payer. Previously validated questions on resource utilization will be administered as part of the baseline, 3-, 6-, and 12-month assessments. | |
| Body Composition | The BOD POD | |
| Anthropometrics | Measurements of body fat including height, weight, BMI, waist circumference, waist-to-hip ratio, and skinfold thickness will be obtained at baseline, 3-, 6-, and 12-month visits. | |
Data Collection Instruments
| Measure | Data Collected | Method |
|---|---|---|
| Information | This will be measured by the 24-item Diabetes Knowledge Questionnaire (DKQ) [ | |
| Motivation | This will be measured by the 8-item Diabetes Empowerment Scale-Short Form (DES-SF) [ | |
| Self-Efficacy | This will be measured by the perceived diabetes self-management scale (PDSMS) [ | |
| Behavioral Skills | This will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA) scale [ | |
| Treatment Credibility | To assess for differences in outcome expectancy, a modified treatment credibility scale developed by Borkovec and Nau (1972) will be used [ | |
| Demographics | Previously validated items from the 2002 National Health Interview Survey [ | |
| Quality of Life | Quality of life will be measured by the SF-12 [ | |
| Social support | The Medical Outcomes Study (MOS) Social Support Survey [ | |
| Health Literacy | The abbreviated version of the Test of Functional Health Literacy in Adults (S-TOFHLA) [ | |
| Depression | The PHQ-9 is a brief questionnaire that scores each of the 9 DSM-IV criteria for depression [ | |
| Medical Comorbidity | The patient's history of medical comorbidity will be documented using a standardized and validated questionnaire(ref#200) [ | |
| Self-Reported Medication Adherence | This will be measured with the new 8-item self-report Morisky Medication Adherence Scale (MMAS) [ | |
| Diabetes Fatalism | This will be measured with the 12-item Diabetes Fatalism Scales (DFS) [ | |
| Service Delivery Perceptions | This will be assessed with 5 items that have been previously validated in mental health studies. The items were slightly modified to be relevant to diabetes. | |
| Assessment of ECAPS Use | A brief 8-item scale will be used to assess the ease of use of the electronic medication adherence pill bottle. | |
Figure 1Design and Study Flow.